These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 34556546)
1. Frequency, severity and costs of flares increase with disease severity in newly diagnosed systemic lupus erythematosus: a real-world cohort study, United States, 2004-2015. Hammond ER; Desta B; Near AM; Wang X; Jiang M Lupus Sci Med; 2021 Sep; 8(1):. PubMed ID: 34556546 [TBL] [Abstract][Full Text] [Related]
2. The cost of flares among patients with systemic lupus erythematosus with and without lupus nephritis in the United States. Bell CF; Huang SP; Cyhaniuk A; Averell CM Lupus; 2023 Feb; 32(2):301-309. PubMed ID: 36542670 [TBL] [Abstract][Full Text] [Related]
3. Disease severity and economic burden in Japanese patients with systemic lupus erythematosus: A retrospective, observational study. Tanaka Y; Mizukami A; Kobayashi A; Ito C; Matsuki T Int J Rheum Dis; 2018 Aug; 21(8):1609-1618. PubMed ID: 30146745 [TBL] [Abstract][Full Text] [Related]
4. Disease and economic burden increase with systemic lupus erythematosus severity 1 year before and after diagnosis: a real-world cohort study, United States, 2004-2015. Jiang M; Near AM; Desta B; Wang X; Hammond ER Lupus Sci Med; 2021 Sep; 8(1):. PubMed ID: 34521733 [TBL] [Abstract][Full Text] [Related]
5. Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes. Oglesby A; Korves C; Laliberté F; Dennis G; Rao S; Suthoff ED; Wei R; Duh MS Appl Health Econ Health Policy; 2014 Apr; 12(2):179-90. PubMed ID: 24573911 [TBL] [Abstract][Full Text] [Related]
6. Retrospective Analysis of Disease Severity, Health Care Resource Utilization, and Costs Among Patients Initiating Belimumab for the Treatment of Systemic Lupus Erythematosus. Lokhandwala T; Coutinho AD; Bell CF Clin Ther; 2021 Aug; 43(8):1320-1335. PubMed ID: 34243966 [TBL] [Abstract][Full Text] [Related]
7. Clinical and economic characterization of mild, moderate, and severe systemic lupus erythematosus: Real-world observation across payer channels in the United States. Wu SS; Perry A; Tkacz J; Bryant G J Manag Care Spec Pharm; 2023 Sep; 29(9):1010-1020. PubMed ID: 37610115 [No Abstract] [Full Text] [Related]
8. Within-trial economic analysis of flare data from the BLISS-SC trial of subcutaneous belimumab in systemic lupus erythematosus. Lokhandwala T; Yue B; Coutinho AD; Bell CF Lupus Sci Med; 2021 Feb; 8(1):. PubMed ID: 33558436 [TBL] [Abstract][Full Text] [Related]
9. Healthcare utilization and cost of systemic lupus erythematosus in a US managed care health plan. Garris C; Jhingran P; Bass D; Engel-Nitz NM; Riedel A; Dennis G J Med Econ; 2013; 16(5):667-77. PubMed ID: 23425294 [TBL] [Abstract][Full Text] [Related]
10. Costs associated with severe and nonsevere systemic lupus erythematosus in Canada. Clarke AE; Urowitz MB; Monga N; Hanly JG Arthritis Care Res (Hoboken); 2015 Mar; 67(3):431-6. PubMed ID: 25185936 [TBL] [Abstract][Full Text] [Related]
11. How should lupus flares be measured? Deconstruction of the safety of estrogen in lupus erythematosus national assessment-systemic lupus erythematosus disease activity index flare index. Thanou A; Chakravarty E; James JA; Merrill JT Rheumatology (Oxford); 2014 Dec; 53(12):2175-81. PubMed ID: 24729400 [TBL] [Abstract][Full Text] [Related]
12. An evaluation of costs associated with overall organ damage in patients with systemic lupus erythematosus in the United States. Bell CF; Ajmera MR; Meyers J Lupus; 2022 Feb; 31(2):202-211. PubMed ID: 35060407 [TBL] [Abstract][Full Text] [Related]
13. Healthcare utilization and costs of systemic lupus erythematosus in Medicaid. Kan HJ; Song X; Johnson BH; Bechtel B; O'Sullivan D; Molta CT Biomed Res Int; 2013; 2013():808391. PubMed ID: 23484162 [TBL] [Abstract][Full Text] [Related]
14. The Impact of Systemic Lupus Erythematosus Flares on Clinical and Economic Outcomes: The CHAMOMILE Claims Database Study in Germany. Ding B; Pignot M; Garal-Pantaler E; Villinger B; Schefzyk S; Desta B; Stirnadel-Farrant HA; Schwarting A Rheumatol Ther; 2024 Apr; 11(2):285-299. PubMed ID: 38252212 [TBL] [Abstract][Full Text] [Related]
15. Healthcare Costs and Utilization for Patients With Systemic Lupus Erythematosus in China: A National Claims Database Study. He X; Lloyd E; Cooper S; Li L; Chauhan D; Juliao P; Quasny H; Bao C Value Health Reg Issues; 2023 Sep; 37():88-96. PubMed ID: 37379801 [TBL] [Abstract][Full Text] [Related]
16. The economic burden of systemic lupus erythematosus in commercially- and medicaid-insured populations in the United States. Clarke AE; Yazdany J; Kabadi SM; Durden E; Winer I; Griffing K; Costenbader KH Semin Arthritis Rheum; 2020 Aug; 50(4):759-768. PubMed ID: 32531505 [TBL] [Abstract][Full Text] [Related]
17. The impact of flare on disease costs of patients with systemic lupus erythematosus. Zhu TY; Tam LS; Lee VW; Lee KK; Li EK Arthritis Rheum; 2009 Sep; 61(9):1159-67. PubMed ID: 19714597 [TBL] [Abstract][Full Text] [Related]
18. [Cost of systemic lupus erythematosus for adult patients with active and treated disease in France (LUCIE study)]. Amoura Z; Deligny C; Pennaforte JL; Hamidou M; Blanco P; Hachulla E; Pourrat J; Queyrel V; Garofano A; Maurel F; Levy-Bachelot L; Boucot I Rev Med Interne; 2014 Nov; 35(11):700-8. PubMed ID: 24630588 [TBL] [Abstract][Full Text] [Related]
19. Predictors of flare-related inpatient or emergency department stay in systemic lupus erythematosus: A real-world analysis of Medicaid claims in the United States. Wu SS; Perry A; Zimmerman NM; Bryant G J Manag Care Spec Pharm; 2024 Jan; 30(1):61-70. PubMed ID: 38153861 [TBL] [Abstract][Full Text] [Related]
20. Clinical profile and direct medical cost of care of adults presenting with systemic lupus erythematosus in Italy. Doria A; Iaccarino L; La Montagna G; Mathieu A; Piga M; Galeazzi M; Iuliano A; Maurel FB; Garofano AM; Perna AG; Porcasi RE Clin Exp Rheumatol; 2015; 33(3):375-84. PubMed ID: 26005879 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]